Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
CRANBURY, N.J., Dec. 23, 2016 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 10, 2017 at 8:30am PT.
An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044 Media: MWW PR Sid Dinsay [email protected] (646) 381-9017
